Appili Therapeutics Inc. (TSX: APLI)
Canada
· Delayed Price · Currency is CAD | Market Cap | 4.24M |
| Revenue (ttm) | 1.15M |
| Net Income (ttm) | -5.34M |
| Shares Out | 121.27M |
| EPS (ttm) | -0.04 |
| PE Ratio | n/a |
| Forward PE | 2.38 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 27,147 |
| Open | 0.0300 |
| Previous Close | 0.0350 |
| Day's Range | 0.0300 - 0.0350 |
| 52-Week Range | 0.0250 - 0.0800 |
| Beta | 1.15 |
| Analysts | n/a |
| Price Target | 0.15 (+328.57%) |
| Earnings Date | Jun 21, 2024 |
About Appili Therapeutics
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifa... [Read more]
Financial Performance
In 2022, APLI's revenue was 334,177, a decrease of -75.97% compared to the previous year's 1.39 million. Losses were -9.24 million, -63.20% less than in 2021.
Financial StatementsNews
Appili Therapeutics Announces Additional Bridge Loan from Bloom Burton & Co.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, April 26, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink:...
Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Stryve Foods, Inc. (NASDAQ: SNAX) fell sharply during Tuesday’s session following a fourth-quarter revenue miss. Stryve Foods posted adjusted loss of $1.90 per share, versus market estimate...
Aditxt signs agreement to acquire Appili Therapeutics
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, today annou...
Appili Therapeutics Signs Definitive Agreement to be Acquired by Aditxt, Inc.
Transaction consideration provides a significant premium to the Appili shareholders Combined enterprise expected to provide enhanced synergies and resources to advance key programs NOT FOR DISTRIBUTIO...
Researchers Publish Manuscript on the Prevention and Emergency Response to Tularemia Outbreaks
A review of Russian and English literature suggests that Appili's biodefense program ATI-1701 may have a role in preventing tularemia in Ukraine A review of Russian and English literature suggests tha...
Appili Therapeutics reports Q3 results
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024
FDA approved LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL Additional USAFA funding commitment from the U.S. Air Force Academy, intended to advance the ATI-1701 program toward an IND ...
Appili Therapeutics Announces Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Provides Update on Bridge Loan
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases an...
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2024
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases an...
Appili Therapeutics Announces Results of Annual Meeting of Shareholders and Provides Corporate Update
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases a...
Appili Therapeutics Presents at the 10th International Tularemia Conference
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases a...
Appili Therapeutics' shares soar on FDA approval for Llikmez oral antibiotic
Appili Therapeutics Inc (TSX-V:APLI) shares rallied after it announced the US Food and Drug Administration (FDA) approved its application for a liquid oral reformulation of the antibiotic metronidazol...
Appili Therapeutics Announces U.S. FDA Approval of LIKMEZ™ (ATI-1501) Metronidazole Oral Suspension
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases an...
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2024
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases an...
Appili Therapeutics Announces Bridge Loan from Bloom Burton & Co.
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases a...
Appili Therapeutics – Press Release Correction
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), announced today a correction to its press release entitled “Appili Therapeutics Re...
Appili Therapeutics Reports Fiscal Year 2023 Financial and Operational Results
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases an...
Appili Therapeutics Announces Issuance of Patent for ATI-1501 Liquid Oral Reformulation of Metronidazole
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases an...
Appili Therapeutics to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
HALIFAX, Nova Scotia--(BUSINESS WIRE)---- $APLI--Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious ...
Appili Therapeutics Appoints Dr. Gary Nabors as Chief Development Officer
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases a...
Appili Therapeutics Announces Additional Funding of CAD$2.5 million under Non-Convertible Secured Loan with Long Zone Holdings
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases a...
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2023
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX: APLI, OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases a...
Appili Therapeutics Announces that FDA accepts the ATI-1501 NDA
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX: APLI) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense,...
Appili Therapeutics Appoints Dr. Carl Gelhaus and Arthur Baran to support the ATI-1701 Biodefense Vaccine Program
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases...